An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2006-02-01

Summary

Multicenter, randomized, double-blind, placebo-controlled, 5-arm, dose-ranging study to assess the efficacy of subcutaneous injections of Golimumab (CNTO 148), 50 or 100 mg, at either 2- or 4- week intervals in subjects with active RA despite MTX therapy.

• Phase: Phase 2

Details

• Lead Sponsor: Centocor, Inc.
• Collaborator: Centocor BV
• Treatments: Golimumab; Infliximab; Methotrexate